Lifecore Biomedical (NASDAQ:LFCR) Announces Earnings Results

Lifecore Biomedical (NASDAQ:LFCR) issued its quarterly earnings data on Wednesday. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03, FiscalAI reports. The business had revenue of $34.17 million during the quarter, compared to analyst estimates of $32.02 million.

Here are the key takeaways from Lifecore Biomedical’s conference call:

• Reaffirmed 2026 guidance for revenue of $120 million–$125 million and adjusted EBITDA of $20.5 million–$25 million, with stronger CDMO revenue expected in the second half, particularly in Q4.
• Contractually committed fill-finish demand from Lifecore’s largest customer is expected to double in 2027 and increase more than 200% in 2028 versus 2026, while a successful PMDA inspection supports potential expansion into Japan.
• The company added six pipeline programs during the quarter and nine year-to-date, including late-stage and commercial site-transfer opportunities; management believes 11 existing development programs could commercialize by the end of 2028.
• Second-quarter revenue fell 6.2% to $34.2 million, while six-month revenue declined 19.9% to $57.4 million; adjusted EBITDA decreased to $8.6 million in the quarter and $9.6 million for the six-month period, and the quarterly net loss widened to $6.2 million.
• Liquidity improved to approximately $38.8 million, but potential Series A preferred payments are not due until December 2028 and would require lender approval; unpaid amounts would accrue interest at 1% per month.

Lifecore Biomedical Price Performance

Shares of NASDAQ LFCR traded up $0.01 during midday trading on Wednesday, reaching $4.36. 85,872 shares of the stock were exchanged, compared to its average volume of 239,130. The business has a 50-day simple moving average of $5.04 and a two-hundred day simple moving average of $5.63. Lifecore Biomedical has a 12 month low of $3.63 and a 12 month high of $8.98. The company has a market capitalization of $163.62 million, a price-to-earnings ratio of -4.66 and a beta of 1.08.

Institutional Investors Weigh In On Lifecore Biomedical

Hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. bought a new stake in Lifecore Biomedical during the second quarter worth about $3,081,000. Squarepoint Ops LLC increased its stake in Lifecore Biomedical by 385.9% in the third quarter. Squarepoint Ops LLC now owns 150,909 shares of the company’s stock valued at $1,111,000 after purchasing an additional 119,851 shares in the last quarter. Millennium Management LLC raised its holdings in Lifecore Biomedical by 86.2% during the fourth quarter. Millennium Management LLC now owns 251,705 shares of the company’s stock worth $2,059,000 after buying an additional 116,500 shares during the last quarter. Quinn Opportunity Partners LLC raised its position in Lifecore Biomedical by 31.5% in the 4th quarter. Quinn Opportunity Partners LLC now owns 242,670 shares of the company’s stock valued at $1,985,000 after buying an additional 58,189 shares during the last quarter. Finally, State Street Corp increased its stake in Lifecore Biomedical by 8.5% in the 4th quarter. State Street Corp now owns 585,386 shares of the company’s stock valued at $4,788,000 after buying an additional 46,102 shares during the last quarter. Institutional investors and hedge funds own 83.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Barrington Research raised their price target on shares of Lifecore Biomedical from $6.00 to $6.50 and gave the company an “outperform” rating in a report on Tuesday, June 16th. Zacks Research upgraded Lifecore Biomedical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Wall Street Zen raised Lifecore Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Weiss Ratings downgraded shares of Lifecore Biomedical from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $6.50.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.